Literature DB >> 9499088

Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette.

B Massie1, F Couture, L Lamoureux, D D Mosser, C Guilbault, P Jolicoeur, F Bélanger, Y Langelier.   

Abstract

We have constructed two new adenovirus expression cassettes that expand both the range of genes which can be expressed with adenovirus vectors (AdV) and the range of cells in which high-level expression can be attained. By inclusion of a tetracycline-regulated promoter in the transfer vector pAdTR5, it is now possible to generate recombinant adenoviruses expressing proteins that are either cytotoxic or that interfere with adenovirus replication. We have used this strategy to generate a recombinant adenovirus encoding a deletion in the R1 subunit [R1(delta2-357)] of the herpes simplex virus type 2 ribonucleotide reductase. Cell lines expressing the tetracycline-regulated transactivator (tTA) from an integrated vector or following infection with an AdV expressing tTA are able to produce deltaR1 protein at a level approaching 10% total cell protein (TCP) when infected with Ad5TR5 deltaR1 before they subsequently die. To our knowledge, this is the first report of the overexpression of a toxic gene product with AdV. We have also constructed a new constitutive adenovirus expression cassette based on an optimized cytomegalovirus immediate-early promoter-enhancer that allows the expression of recombinant proteins at a level greater than 20% TCP in nonpermissive cell lines. Together, these new expression cassettes significantly improve the utility of the adenovirus system for high-level expression of recombinant proteins in animal cells and will undoubtedly find useful applications in gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499088      PMCID: PMC109527          DOI: 10.1128/JVI.72.3.2289-2296.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Inducible gene expression systems for higher eukaryotic cells.

Authors:  M Gossen; A L Bonin; S Freundlieb; H Bujard
Journal:  Curr Opin Biotechnol       Date:  1994-10       Impact factor: 9.740

Review 2.  Gene therapy using adenoviral vectors.

Authors:  B C Trapnell; M Gorziglia
Journal:  Curr Opin Biotechnol       Date:  1994-12       Impact factor: 9.740

3.  Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice.

Authors:  M Manthorpe; F Cornefert-Jensen; J Hartikka; J Felgner; A Rundell; M Margalith; V Dwarki
Journal:  Hum Gene Ther       Date:  1993-08       Impact factor: 5.695

4.  Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells.

Authors:  A Garnier; J Côté; I Nadeau; A Kamen; B Massie
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

5.  Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer.

Authors:  K N Wills; D C Maneval; P Menzel; M P Harris; S Sutjipto; M T Vaillancourt; W M Huang; D E Johnson; S C Anderson; S F Wen
Journal:  Hum Gene Ther       Date:  1994-09       Impact factor: 5.695

6.  Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors.

Authors:  W Sheay; S Nelson; I Martinez; T H Chu; S Bhatia; R Dornburg
Journal:  Biotechniques       Date:  1993-11       Impact factor: 1.993

7.  The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha.

Authors:  E White; P Sabbatini; M Debbas; W S Wold; D I Kusher; L R Gooding
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

8.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

Authors:  G W Wilkinson; A Akrigg
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

9.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.

Authors:  D Resnitzky; M Gossen; H Bujard; S I Reed
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

10.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity.

Authors:  G Acsadi; A Jani; B Massie; M Simoneau; P Holland; K Blaschuk; G Karpati
Journal:  Hum Mol Genet       Date:  1994-04       Impact factor: 6.150

View more
  22 in total

1.  Cytotoxic potency of cardiotoxin from Naja sputatrix: development of a new cytolytic assay.

Authors:  Donghui Ma; Arunmozhiarasi Armugam; Kandiah Jeyaseelan
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

Review 2.  Therapeutic strategies for Parkinson's disease: the ancient meets the future--traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells.

Authors:  Xuan Wang; Xi-Bin Liang; Feng-Qiao Li; Hui-Fang Zhou; Xian-Yu Liu; Jian-Jun Wang; Xiao-Min Wang
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

3.  New adenovirus vectors for protein production and gene transfer.

Authors:  B Massie; D D Mosser; M Koutroumanis; I Vitté-Mony; L Lamoureux; F Couture; L Paquet; C Guilbault; J Dionne; D Chahla; P Jolicoeur; Y Langelier
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

4.  Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.

Authors:  Guangliang Liu; Fangfang Zhang; Ruixue Wang; Lucille London; Steven D London
Journal:  FASEB J       Date:  2014-01-03       Impact factor: 5.191

5.  Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments.

Authors:  M Molin; M C Shoshan; K Ohman-Forslund; S Linder; G Akusjärvi
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Authors:  Larissa H Haut; Amanda L Gill; Raj K Kurupati; Ang Bian; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Xiang Yang Zhou; Hildegund C J Ertl
Journal:  Hum Gene Ther Methods       Date:  2016-09-07       Impact factor: 2.396

7.  Nuclear translocation controlled by alternatively spliced isoforms inactivates the QUAKING apoptotic inducer.

Authors:  J Pilotte; D Larocque; S Richard
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

8.  Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72.

Authors:  A B Meriin; J A Yaglom; V L Gabai; L Zon; S Ganiatsas; D D Mosser; L Zon; M Y Sherman
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

9.  Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death.

Authors:  V L Gabai; J A Yaglom; V Volloch; A B Meriin; T Force; M Koutroumanis; B Massie; D D Mosser; M Y Sherman
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

10.  Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72.

Authors:  Julia Yaglom; Cornelia O'Callaghan-Sunol; Vladimir Gabai; Michael Y Sherman
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.